Key result
PCI with everolimus-eluting stents yields higher MACE rates than CABG in multivessel CAD.
Why the study?
Does PCI with everolimus-eluting stents improve major adverse cardiovascular events in patients with multivessel coronary artery disease compared to CABG?
Does PCI with everolimus-eluting stents improve major adverse cardiovascular events in patients with multivessel coronary artery disease compared to CABG?
In patients with multivessel coronary artery disease, CABG is associated with a lower rate of major adverse cardiovascular events compared to PCI with everolimus-eluting stents.
No takes yet. Share an insight, caveat, or question.
Prefer CABG over everolimus-eluting PCI in multivessel CAD; challenges consensus on PCI equivalence.
Park et al. (2015) studied this question. In patients with multivessel coronary artery disease, PCI using everolimus-eluting stents led to a higher rate of major adverse cardiovascular events compared to CABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: